NasdaqGS:NTRABiotechs
Assessing Natera (NTRA) Valuation After New Signatera Breast Cancer Study Results
Why the latest Signatera study matters for Natera (NTRA) shareholders
Natera (NTRA) is back in focus after publishing new Clinical Cancer Research data on its Signatera test, showing how older women with early stage ER+/HER2- breast cancer might be treated with endocrine therapy alone.
The prospective study followed women aged 70 and above who chose to skip surgery and receive primary endocrine therapy, with Signatera used regularly alongside imaging and physician assessments to track...